Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200016288> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4200016288 endingPage "30" @default.
- W4200016288 startingPage "30" @default.
- W4200016288 abstract "In the EMPEROR-Reduced Trial, empagliflozin was demonstrated to reduce cardiorenal outcomes and improve quality of life in patients with HFrEF. We examined whether the benefit of empagliflozin was consistent across the doses and combinations of baseline heart failure therapies. The primary outcome of time to cardiovascular (CV) death or hospitalization for heart failure (HHF) was examined in patients receiving ACEi or ARB (RAASi), MRA or beta-blockers (BB) at ≥ 50% or < 50% of target dose. Furthermore, the primary outcome was examined in patients receiving baseline combination therapy: RAASi + BB; RAASi + BB + MRA; and ARNI + BB + MRA. At baseline, of the 3730 patients randomized, 26.8%, 61.5%, and 48.9% were treated with ≥50% of target doses of RAASi, MRA or BB respectively. Additionally, 66.7%, 17.5%, 48.4%, 13.8%, 84.1%, 61.1%, and 13.4% were treated with combination of either RAASi + BB, RAASi + BB (≥50%), RAASi + BB + MRA, RAASi + BB (≥ 50%) + MRA, RAASi or ARNI + BB, RAASi or ARNI + BB + MRA or ARNI + BB + MRA. Across all sub-groups, the hazard ratio for the primary outcome was consistent with the overall estimate of 0.75 (0.65 to 0.86; P < 0.001) in empagliflozin vs. placebo treated patients with no heterogeneity by subgroup interaction (Fig. 1). KCCQ-CSS improved across all subgroups. Tolerability was similar between groups. Empagliflozin's beneficial effects in HFrEF are observed consistently regardless of the doses and combinations of other foundational drugs for heart failure." @default.
- W4200016288 created "2021-12-31" @default.
- W4200016288 creator A5003198623 @default.
- W4200016288 creator A5058448908 @default.
- W4200016288 date "2022-01-01" @default.
- W4200016288 modified "2023-09-27" @default.
- W4200016288 title "Efficacy of Empagliflozin in the EMPEROR-Reduced Trial According to Dose and Combination of Baseline Heart Failure Therapies" @default.
- W4200016288 doi "https://doi.org/10.1016/j.acvdsp.2021.09.067" @default.
- W4200016288 hasPublicationYear "2022" @default.
- W4200016288 type Work @default.
- W4200016288 citedByCount "0" @default.
- W4200016288 crossrefType "journal-article" @default.
- W4200016288 hasAuthorship W4200016288A5003198623 @default.
- W4200016288 hasAuthorship W4200016288A5058448908 @default.
- W4200016288 hasBestOaLocation W42000162881 @default.
- W4200016288 hasConcept C126322002 @default.
- W4200016288 hasConcept C134018914 @default.
- W4200016288 hasConcept C142724271 @default.
- W4200016288 hasConcept C164705383 @default.
- W4200016288 hasConcept C204787440 @default.
- W4200016288 hasConcept C207103383 @default.
- W4200016288 hasConcept C27081682 @default.
- W4200016288 hasConcept C2775887513 @default.
- W4200016288 hasConcept C2777180221 @default.
- W4200016288 hasConcept C2778198053 @default.
- W4200016288 hasConcept C44249647 @default.
- W4200016288 hasConcept C555293320 @default.
- W4200016288 hasConcept C71924100 @default.
- W4200016288 hasConceptScore W4200016288C126322002 @default.
- W4200016288 hasConceptScore W4200016288C134018914 @default.
- W4200016288 hasConceptScore W4200016288C142724271 @default.
- W4200016288 hasConceptScore W4200016288C164705383 @default.
- W4200016288 hasConceptScore W4200016288C204787440 @default.
- W4200016288 hasConceptScore W4200016288C207103383 @default.
- W4200016288 hasConceptScore W4200016288C27081682 @default.
- W4200016288 hasConceptScore W4200016288C2775887513 @default.
- W4200016288 hasConceptScore W4200016288C2777180221 @default.
- W4200016288 hasConceptScore W4200016288C2778198053 @default.
- W4200016288 hasConceptScore W4200016288C44249647 @default.
- W4200016288 hasConceptScore W4200016288C555293320 @default.
- W4200016288 hasConceptScore W4200016288C71924100 @default.
- W4200016288 hasIssue "1" @default.
- W4200016288 hasLocation W42000162881 @default.
- W4200016288 hasOpenAccess W4200016288 @default.
- W4200016288 hasPrimaryLocation W42000162881 @default.
- W4200016288 hasRelatedWork W2137107263 @default.
- W4200016288 hasRelatedWork W2476254724 @default.
- W4200016288 hasRelatedWork W2958440246 @default.
- W4200016288 hasRelatedWork W3198485697 @default.
- W4200016288 hasRelatedWork W4210427521 @default.
- W4200016288 hasRelatedWork W4225666519 @default.
- W4200016288 hasRelatedWork W4288640004 @default.
- W4200016288 hasRelatedWork W4293037419 @default.
- W4200016288 hasRelatedWork W4385494942 @default.
- W4200016288 hasRelatedWork W2035069710 @default.
- W4200016288 hasVolume "14" @default.
- W4200016288 isParatext "false" @default.
- W4200016288 isRetracted "false" @default.
- W4200016288 workType "article" @default.